GlobalData on MSN6d
Eisai and Biogen’s subcutaneous Leqembi set for FDA reviewEisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...
The developer is adding ancillary businesses that support the kind of high-profile companies that have been attracted to the ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...
Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for ...
Laura Bolognesi is leading the B2AlzD2 Joint Lab at UNIBO, with Brazilian universities to develop Alzheimer's drugs from ...
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...
(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics License Application or BLA for lecanemab-irmb (U.S ...
"Among dialysis patients with osteoporosis, denosumab may be more effective than oral bisphosphonates in reducing fracture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback